Doxorubicin as a molecular nanotheranostic agent: effect of doxorubicin encapsulation in micelles or nanoemulsions on the ultrasound-mediated intracellular delivery and nuclear trafficking.

Doxorubicin (DOX) is one of the most commonly used chemotherapeutic drugs and is a popular research tool due to the inherent fluorescence of the DOX molecule. After DOX injection, fluorescence imaging of organs or cells can provide information on drug biodistribution. Therapeutic and imaging capabilities combined in a DOX molecule make it an excellent theranostic agent. However, DOX fluorescence depends on a number of factors that should be taken into consideration when interpreting results of DOX fluorescence measurements. Discussing these problems is the main thrust of the current paper. The sensitivity of DOX fluorescence intensity to DOX concentration, local microenvironment, and interaction with model cellular components is illustrated by fluorescence spectra of paired DOX/phospholipid, DOX/histone, DOX/DNA, and triple DOX/histone/DNA and DOX/phospholipid/DNA systems. DOX fluorescence is dramatically quenched upon intercalation into the DNA; DOX fluorescence is also self-quenched at high concentrations of molecularly dissolved DOX; in contrast, DOX fluorescence is increased after binding to the histone or partitioning into the phospholipid phase of PEG-phospholipid micelles or hydrophobic cores of polymeric micelles. While flow cytometry is commonly used for characterization of DOX intracellular uptake, the above aspects of DOX fluorescence may significantly complicate interpretation of flow cytometry results. High cell fluorescence measured by flow cytometry may provide deceptive information on the actual intracellular DOX concentration and may not correlate with the therapeutic efficacy if DOX does not penetrate into the site of action in cell nuclei. These problems are illustrated in the experiments on the intracellular trafficking of DOX encapsulated in poly(ethylene glycol)-co-polycaprolactone (PEG-PCL) micelles or PEG-PCL stabilized perfluorocarbon nanodroplets, with and without the application of ultrasound used as an external trigger. For efficient encapsulation in micelle cores, DOX is usually deprotonated, which removes the positive charge and enhances hydrophobicity of DOX molecule. It was found that the deprotonated DOX accumulated in the cell cytoplasm but did not penetrate into the cell nuclei. The same was true for the DOX encapsulated in micelles or nanodroplets, which may explain their low therapeutic efficacy in the absence of ultrasound. Ultrasound triggers DOX trafficking into the cell nuclei, which is especially pronounced in the presence of nanoemulsions that convert into microbubbles under the ultrasound action. Microbubble cavitation results in the transient permeabilization of both plasma and nuclear membranes, thus allowing DOX penetration into the cell nuclei, which dramatically enhances therapeutic efficacy of DOX-loaded nanodroplet systems.

[1]  N. Rapoport,et al.  Acoustic activation of drug delivery from polymeric micelles: effect of pulsed ultrasound. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[2]  G. Minotti,et al.  Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy. , 2001, Cancer research.

[3]  J. Shea,et al.  Ultrasonic nanotherapy of pancreatic cancer: lessons from ultrasound imaging. , 2010, Molecular pharmaceutics.

[4]  J B Fowlkes,et al.  Acoustic droplet vaporization for therapeutic and diagnostic applications. , 2000, Ultrasound in medicine & biology.

[5]  D. Christensen,et al.  Microbubble Generation in Phase-Shift Nanoemulsions used as Anticancer Drug Carriers. , 2009, Bubble science engineering and technology.

[6]  Mark Borden,et al.  Ultrasound microbubble contrast agents: fundamentals and application to gene and drug delivery. , 2007, Annual review of biomedical engineering.

[7]  N. Rapoport,et al.  Intracellular distribution and intracellular dynamics of a spin-labeled analogue of doxorubicin fluorescence and EPR spectroscopy. , 1998, Journal of pharmaceutical sciences.

[8]  N. Rapoport Stabilization and activation of Pluronic micelles for tumor-targeted drug delivery , 1999 .

[9]  Y. Bae,et al.  Doxorubicin loaded pH-sensitive micelle targeting acidic extracellular pH of human ovarian A2780 tumor in mice , 2005, Journal of drug targeting.

[10]  Teruo Okano,et al.  Soluble Self-Assembled Block Copolymers for Drug Delivery , 1999, Pharmaceutical Research.

[11]  D. Gewirtz,et al.  Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells. , 1994, Molecular pharmacology.

[12]  Alexander V Kabanov,et al.  Pluronic block copolymers in drug delivery: from micellar nanocontainers to biological response modifiers. , 2002, Critical reviews in therapeutic drug carrier systems.

[13]  D. Christensen,et al.  Factors affecting acoustically triggered release of drugs from polymeric micelles. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[14]  C. Maggi,et al.  Anthracycline metabolism and toxicity in human myocardium: comparisons between doxorubicin, epirubicin, and a novel disaccharide analogue with a reduced level of formation and [4Fe-4S] reactivity of its secondary alcohol metabolite. , 2000, Chemical research in toxicology.

[15]  F. Dosio,et al.  From Conventional to Stealth Liposomes a new Frontier in Cancer Chemotherapy , 2003, Tumori.

[16]  K. Hirao,et al.  Induction of premature senescence in cardiomyocytes by doxorubicin as a novel mechanism of myocardial damage , 2008, Aging cell.

[17]  D. Christensen,et al.  Ultrasound‐enhanced localized chemotherapy of drug‐sensitive and multidrug resistant tumors , 2006 .

[18]  N. Rapoport Physical stimuli-responsive polymeric micelles for anti-cancer drug delivery , 2007 .

[19]  A. Kabanov,et al.  Block copolymer-based formulation of doxorubicin. From cell screen to clinical trials , 1999 .

[20]  A. Paolo,et al.  Liposomal anticancer therapy: pharmacokinetic and clinical aspects. , 2004 .

[21]  R. Chlebowski Adriamycin (doxorubicin) cardiotoxicity: a review. , 1979, The Western journal of medicine.

[22]  D. Christensen,et al.  Cavitation properties of block copolymer stabilized phase-shift nanoemulsions used as drug carriers. , 2010, Ultrasound in medicine & biology.

[23]  G. Minotti,et al.  Doxorubicin metabolism and toxicity in human myocardium: role of cytoplasmic deglycosidation and carbonyl reduction. , 2000, Chemical research in toxicology.

[24]  P. Devarajan,et al.  Engineered nanocarriers of doxorubicin: a current update. , 2008, Critical reviews in therapeutic drug carrier systems.

[25]  Saurabh Datta,et al.  Correlation of cavitation with ultrasound enhancement of thrombolysis. , 2006, Ultrasound in medicine & biology.

[26]  A. Kabanov,et al.  Fundamental Relationships Between the Composition of Pluronic Block Copolymers and Their Hypersensitization Effect in MDR Cancer Cells , 1999, Pharmaceutical Research.

[27]  Alexander V. Kabanov,et al.  Pluronic P85 Increases Permeability of a Broad Spectrum of Drugs in Polarized BBMEC and Caco-2 Cell Monolayers , 1999, Pharmaceutical Research.

[28]  P. Choong,et al.  Review: doxorubicin delivery systems based on chitosan for cancer therapy , 2009 .

[29]  Susannah H Bloch,et al.  Application of Ultrasound to Selectively Localize Nanodroplets for Targeted Imaging and Therapy , 2006, Molecular imaging.

[30]  N. Rapoport Ultrasound Interactions with Polymeric Micelles and Viable Cells , 2004 .

[31]  T. Okano,et al.  Biodistribution of Micelle-Forming Polymer–Drug Conjugates , 1993, Pharmaceutical Research.

[32]  D. Christensen,et al.  Drug delivery in pluronic micelles: effect of high-frequency ultrasound on drug release from micelles and intracellular uptake. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[33]  K. Wallace,et al.  Adriamycin-induced oxidative mitochondrial cardiotoxicity , 2006, Cell Biology and Toxicology.

[34]  K. Kataoka,et al.  Preclinical and clinical studies of anticancer agent‐incorporating polymer micelles , 2009, Cancer science.

[35]  O. Kripfgans,et al.  Acoustic droplet vaporization threshold: effects of pulse duration and contrast agent , 2007, IEEE Transactions on Ultrasonics, Ferroelectrics and Frequency Control.

[36]  Christine Allen,et al.  The effects of particle size and molecular targeting on the intratumoral and subcellular distribution of polymeric nanoparticles. , 2010, Molecular pharmaceutics.

[37]  Donald W. Miller,et al.  Pluronic P85 enhances the delivery of digoxin to the brain: in vitro and in vivo studies. , 2001, The Journal of pharmacology and experimental therapeutics.

[38]  Donald W. Miller,et al.  Pluronic P 85 Enhances the Delivery of Digoxin to the Brain : In Vitro and in Vivo Studies , 2001 .

[39]  L. Marnett Oxy radicals, lipid peroxidation and DNA damage. , 2002, Toxicology.

[40]  P. Carson,et al.  The role of inertial cavitation in acoustic droplet vaporization , 2008, IEEE Transactions on Ultrasonics, Ferroelectrics and Frequency Control.

[41]  Kullervo Hynynen,et al.  Macromolecular delivery across the blood-brain barrier. , 2009, Methods in molecular biology.

[42]  K. Wallace Adriamycin-induced interference with cardiac mitochondrial calcium homeostasis , 2007, Cardiovascular Toxicology.

[43]  R E Apfel,et al.  Thresholds for transient cavitation produced by pulsed ultrasound in a controlled nuclei environment. , 1989, The Journal of the Acoustical Society of America.

[44]  M. Morris,et al.  Cell-penetrating peptides: tools for intracellular delivery of therapeutics , 2005, Cellular and Molecular Life Sciences CMLS.

[45]  Christine Allen,et al.  In Vivo Distribution of Polymeric Nanoparticles at the Whole-Body, Tumor, and Cellular Levels , 2010, Pharmaceutical Research.

[46]  G. Plosker Pegylated Liposomal Doxorubicin , 2012, Drugs.

[47]  Natalia Vykhodtseva,et al.  Focal disruption of the blood-brain barrier due to 260-kHz ultrasound bursts: a method for molecular imaging and targeted drug delivery. , 2006, Journal of neurosurgery.

[48]  G. Scambia,et al.  Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome). , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[49]  A. Kabanov,et al.  Mixed Polymer Micelles of Amphiphilic and Cationic Copolymers for Delivery of Antisense Oligonucleotides , 2004, Journal of drug targeting.

[50]  L. Bromberg Polymeric micelles in oral chemotherapy. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[51]  T. Okano,et al.  Characterization of physical entrapment and chemical conjugation of adriamycin in polymeric micelles and their design for in vivo delivery to a solid tumor. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[52]  F. Zunino,et al.  The interaction of daunorubicin and doxorubicin with DNA and chromatin. , 1980, Biochimica et biophysica acta.

[53]  J. Cummings,et al.  DNA topoisomerase I and II as targets for rational design of new anticancer drugs. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

[54]  Alexander V Kabanov,et al.  Pluronic block copolymers as modulators of drug efflux transporter activity in the blood-brain barrier. , 2003, Advanced drug delivery reviews.

[55]  H. Fain,et al.  Controlled and targeted tumor chemotherapy by micellar-encapsulated drug and ultrasound. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[56]  Muniruzzaman,et al.  Intracellular uptake of Pluronic copolymer: effects of the aggregation state , 2002 .

[57]  L. Gianni,et al.  Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity , 2004, Pharmacological Reviews.

[58]  G. Prestwich,et al.  Intracellular uptake and trafficking of Pluronic micelles in drug-sensitive and MDR cells: effect on the intracellular drug localization. , 2002, Journal of pharmaceutical sciences.

[59]  A. Rich,et al.  Structural comparison of anticancer drug-DNA complexes: adriamycin and daunomycin. , 1990, Biochemistry.

[60]  Lisa Brannon-Peppas,et al.  Active targeting schemes for nanoparticle systems in cancer therapeutics. , 2008, Advanced drug delivery reviews.

[61]  J. Kopeček,et al.  HPMA copolymers: origins, early developments, present, and future. , 2010, Advanced drug delivery reviews.

[62]  R. Rosenfeld,et al.  Deciphering the fluorescence signature of daunomycin and doxorubicin. , 1998, Biophysical chemistry.

[63]  J. Fréchet,et al.  pH-Responsive copolymer assemblies for controlled release of doxorubicin. , 2005, Bioconjugate chemistry.

[64]  Zhong-gao Gao,et al.  Ultrasound-enhanced chemotherapy of drug-resistant breast cancer tumors by micellar-encapsulated Paclitaxel , 2006 .

[65]  Yechezkel Barenholz,et al.  Pharmacokinetics of Pegylated Liposomal Doxorubicin , 2003, Clinical pharmacokinetics.

[66]  Hua Ai,et al.  Micellar carriers based on block copolymers of poly(ε-caprolactone) and poly(ethylene glycol) for doxorubicin delivery , 2004 .

[67]  T. Okano,et al.  Development of the polymer micelle carrier system for doxorubicin. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[68]  T. Okano,et al.  Doxorubicin-loaded poly(ethylene glycol)-poly(beta-benzyl-L-aspartate) copolymer micelles: their pharmaceutical characteristics and biological significance. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[69]  Alexander V Kabanov,et al.  Pluronic block copolymers for overcoming drug resistance in cancer. , 2002, Advanced drug delivery reviews.

[70]  E. Unger,et al.  Gene Delivery Using Ultrasound Contrast Agents , 2001, Echocardiography.

[71]  G Aubel-Sadron,et al.  Daunorubicin and doxorubicin, anthracycline antibiotics, a physicochemical and biological review. , 1984, Biochimie.

[72]  A. Kabanov,et al.  Distribution kinetics of a micelle-forming block copolymer Pluronic P85. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[73]  N. Rapoport,et al.  Mechanism of the ultrasonic activation of micellar drug delivery. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[74]  P. Carson,et al.  On the acoustic vaporization of micrometer-sized droplets. , 2004, The Journal of the Acoustical Society of America.

[75]  Alexander V Kabanov,et al.  Differential metabolic responses to pluronic in MDR and non-MDR cells: a novel pathway for chemosensitization of drug resistant cancers. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[76]  M. Woydt,et al.  In vivo droplet vaporization for occlusion therapy and phase aberration correction , 2002, IEEE Transactions on Ultrasonics, Ferroelectrics and Frequency Control.

[77]  Kullervo Hynynen,et al.  Ultrasound for drug and gene delivery to the brain. , 2008, Advanced drug delivery reviews.

[78]  A. Hauschild,et al.  Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts. , 2008, European Journal of Cancer.

[79]  Alexander V Kabanov,et al.  Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[80]  J. Herron,et al.  Micellar delivery of doxorubicin and its paramagnetic analog, ruboxyl, to HL-60 cells: effect of micelle structure and ultrasound on the intracellular drug uptake. , 1999, Journal of controlled release : official journal of the Controlled Release Society.

[81]  J. Shea,et al.  Controlled and targeted tumor chemotherapy by ultrasound-activated nanoemulsions/microbubbles. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[82]  You Han Bae,et al.  Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[83]  A. Kabanov,et al.  Anthracycline antibiotics non-covalently incorporated into the block copolymer micelles: in vivo evaluation of anti-cancer activity. , 1996, British Journal of Cancer.

[84]  J. Fréchet,et al.  Dendrimers and dendritic polymers in drug delivery. , 2005, Drug discovery today.

[85]  Douglas A Christensen,et al.  Drug-loaded nano/microbubbles for combining ultrasonography and targeted chemotherapy. , 2008, Ultrasonics.

[86]  A. Gabizon Emerging Role of Liposomal Drug Carrier Systems in Cancer Chemotherapy , 2003, Journal of liposome research.

[87]  Vladimir P Torchilin,et al.  Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. , 2005, Advanced drug delivery reviews.

[88]  A. Kabanov,et al.  New technologies for drug delivery across the blood brain barrier. , 2004, Current pharmaceutical design.

[89]  Michael D. Abràmoff,et al.  Image processing with ImageJ , 2004 .

[90]  K. Ulbrich,et al.  Spectral analysis of doxorubicin accumulation and the indirect quantification of its DNA intercalation. , 2010, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[91]  P. Carson,et al.  Acoustic droplet vaporization for temporal and spatial control of tissue occlusion: a kidney study , 2005, IEEE Transactions on Ultrasonics, Ferroelectrics and Frequency Control.

[92]  Theresa M Allen,et al.  Advantages of liposomal delivery systems for anthracyclines. , 2004, Seminars in oncology.

[93]  Atsushi Harada,et al.  Design of environment-sensitive supramolecular assemblies for intracellular drug delivery: polymeric micelles that are responsive to intracellular pH change. , 2003, Angewandte Chemie.

[94]  C. Allen,et al.  Formulation of drugs in block copolymer micelles: drug loading and release. , 2006, Current pharmaceutical design.

[95]  V. Adamo,et al.  Pegylated liposomal doxorubicin and gemcitabine in the front-line treatment of recurrent/metastatic breast cancer: a multicentre phase II study , 2008, British Journal of Cancer.

[96]  Katherine W Ferrara,et al.  Driving delivery vehicles with ultrasound. , 2008, Advanced drug delivery reviews.

[97]  Zhong-gao Gao,et al.  Multifunctional nanoparticles for combining ultrasonic tumor imaging and targeted chemotherapy. , 2007, Journal of the National Cancer Institute.

[98]  E. Unger,et al.  Therapeutic applications of lipid-coated microbubbles. , 2004, Advanced drug delivery reviews.

[99]  N. Rapoport Combined cancer therapy by micellar-encapsulated drug and ultrasound. , 2004, International journal of pharmaceutics.

[100]  You Han Bae,et al.  Polymeric micelle for tumor pH and folate-mediated targeting. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[101]  Jennifer I. Hare,et al.  Pharmacokinetics and pharmacodynamics of lipidic nano-particles in cancer. , 2006, Anti-cancer agents in medicinal chemistry.

[102]  H. Fain,et al.  Ultrasound-enhanced tumor targeting of polymeric micellar drug carriers. , 2004, Molecular pharmaceutics.

[103]  S. Siegel,et al.  Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells. , 1976, Cancer research.